EP. 1: Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC
Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.
EP. 2: Dr Wakelee on Key Trials With Perioperative Immunotherapy in Early-Stage NSCLC
Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.
EP. 3: Perioperative Trials Add to Growing Immunotherapy Landscape in Early-Stage NSCLC
Emerging data continue to shape perioperative therapy decisions for patients with early-stage non–small cell lung cancer.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL
Learning to Dance
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer
Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma